Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov 2:375:e068060.
doi: 10.1136/bmj-2021-068060.

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

Nicole Ezer  1   2 , Sara Belga  3 , Nick Daneman  4 , Adrienne Chan  4 , Benjamin M Smith  5   2 , Shay-Anne Daniels  3 , Kristen Moran  6 , Charlotte Besson  2 , Louisa Y Smyth  6 , Susan J Bartlett  2   7 , Andrea Benedetti  2   7 , James G Martin  5   2 , Todd C Lee  2   6   7   8 , Emily G McDonald  2   6   7   9
Affiliations
Clinical Trial

Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

Nicole Ezer et al. BMJ. .

Abstract

Objective: To determine if inhaled and intranasal ciclesonide are superior to placebo at decreasing respiratory symptoms in adult outpatients with covid-19.

Design: Randomised, double blind, placebo controlled trial.

Setting: Three Canadian provinces (Quebec, Ontario, and British Columbia).

Participants: 203 adults aged 18 years and older with polymerase chain reaction confirmed covid-19, presenting with fever, cough, or dyspnoea.

Intervention: Participants were randomised to receive either inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) or metered dose inhaler and nasal saline placebos for 14 days.

Main outcome measures: The primary outcome was symptom resolution at day 7. Analyses were conducted on the modified intention-to-treat population (participants who took at least one dose of study drug and completed one follow-up survey) and adjusted for stratified randomisation by sex.

Results: The modified intention-to-treat population included 203 participants: 105 were randomly assigned to ciclesonide (excluding two dropouts and one loss to follow-up) and 98 to placebo (excluding three dropouts and six losses to follow-up). The median age was 35 years (interquartile range 27-47 years) and 54% were women. The proportion of participants with resolution of symptoms by day 7 did not differ significantly between the intervention group (42/105, 40%) and control group (34/98, 35%); absolute adjusted risk difference 5.5% (95% confidence interval -7.8% to 18.8%). Results might be limited to the population studied, which mainly included younger adults without comorbidities. The trial was stopped early, therefore could have been underpowered.

Conclusion: Compared with placebo, the combination of inhaled and intranasal ciclesonide did not show a statistically significant increase in resolution of symptoms among healthier young adults with covid-19 presenting with prominent respiratory symptoms. As evidence is insufficient to determine the benefit of inhaled and intranasal corticosteroids in the treatment of covid-19, further research is needed.

Trial registration: ClinicalTrials.gov NCT04435795.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: NE reports grants from Fonds de Recherche du Québec en Santé, grants from Rossy Cancer Network, non-financial support from COVIS Pharma (study drug donation), advisory board fees from Glaxo Smith Kline, advisory board fees from Astra Zeneca, grants from Canadian Institute of Health Research, grants from MEDTEQ, outside the submitted work. SB reports personal fees from Verity Pharma and from Merck, outside the submitted work. All remaining authors declare no support from any organisation for the submitted; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Flow of participants through study
See this image and copyright information in PMC

References

    1. Horby P, Lim WS, Emberson JR, et al. RECOVERY Collaborative Group . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693-704. 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. Lawler PR, Goligher EC, Berger JS, et al. ATTACC Investigators. ACTIV-4a Investigators. REMAP-CAP Investigators . Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021;385:790-802. - PMC - PubMed
    1. Gordon AC, Mouncey PR, Al-Beidh F, et al. REMAP-CAP Investigators . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384:1491-502. 10.1056/NEJMoa2100433. - DOI - PMC - PubMed
    1. Weinreich DM, Sivapalasingam S, Norton T, et al. Trial Investigators . REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med 2021;384:238-51. 10.1056/NEJMoa2035002. - DOI - PMC - PubMed
    1. Jeon S, Ko M, Lee J, et al. . Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. Antimicrob Agents Chemother 2020;64:e00819-20. 10.1128/AAC.00819-20. - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data